TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06264934

Intervention type: DEVICE
Intervention: Breast scan using the Z-scanner
Description: Four repeated scans of both breasts using the Z-scanner.

Intervention type: DEVICE
Intervention: Breast scan using the Z-scanner
Description: A scan of both breasts using the Z-scanner.
Study: NCT05811247

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AD109
Description: Oral administration at bedtime.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral administration at bedtime.
Study: NCT05629338

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Autologous Spray Dried Plasma
Description: Evaluation of the Safety of Ascending Doses of Autologous Spray Dried Plasma in Healthy Volunteers

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Autologous Spray Dried Plasma
Description: Evaluation of the Safety of Ascending Doses of Autologous Spray Dried Plasma in Healthy Volunteers
Study: NCT05896995

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pilates Exercise
Description: Pilates exercises target the deep muscles of the core, including the abdomen, lower back, hips, and glutes, while also engaging the whole body.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Mckenzie Exercise
Description: The McKenzie Method emphasizes self-treatment and active patient involvement in the management of their condition. It involves a systematic assessment process to determine the most appropriate exercises and interventions for an individual based on their specific symptoms and movement responses.
Study: NCT05592574

Intervention type: OTHER
Intervention: Blood sample
Description: Blood samples required to performe IL-17 Dosage
Study: NCT06126744

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVR-C5252
Description: MVR-C5252 is a genetically modified next generation oncolytic herpes simplex virus 1 (oHSV1) with an active domain of human IL-12 and Fab fragment of anti-PD-1 antibody. This is a Phase 1 open label study designed to determine the safety and tolerability of MVR-C5252. The dose-escalation portion of the study will be conducted in 4 stages to evaluate the safety of infusion and determination of the MTD/RP2D followed by efficacy assessment.
Study: NCT04507854

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Strength, range of motion and functional tests + Questionnaire
Description: Patients undergoing instability surgery will perform amplitude, strength, functional tests and a questionnaire at 6 months of the operation. Then they will be contacted at 12, 18 and 24 months to find out if they have regained their performance level or if they have injured their shoulder again.
Study: NCT05067998

Intervention type: DIETARY_SUPPLEMENT
Intervention: IV Vitamin Infused Therapy Treatment
Description: Vitamin B, C, D, E, K, liquid vitamins, antioxidants, amino acids, and minerals

Intervention type: DIETARY_SUPPLEMENT
Intervention: IV Vitamin Infused Therapy Treatment
Description: Vitamin B, C, D, E, K, liquid vitamins, antioxidants, amino acids, and minerals

Intervention type: DRUG
Intervention: Herbal medicine
Description: Herbal medicine is the use of plants to treat disease and enhance general health and wellbeing. Examples of common herbal health products and supplements include black cohosh, echinacea, garlic, ginkgo, saw palmetto, and St. John's wort just to name a few.

Intervention type: DRUG
Intervention: Herbal medicine
Description: Herbal medicine is the use of plants to treat disease and enhance general health and wellbeing. Examples of common herbal health products and supplements include black cohosh, echinacea, garlic, ginkgo, saw palmetto, and St. John's wort just to name a few.
Study: NCT05414253

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Parallel Assignment
Description: Single-centre randomized, parallel design, clinical trial with a 2 week follow-up

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Parallel Assignment
Description: Single-centre randomized, parallel design, clinical trial with a 2 week follow-up
Study: NCT04748991

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vernakalant
Description: Post operative AF after cardiac surgery. Vernakalant 3mg/kg over 10 minutes followed by 2mg/kg over 10 minutes if still in AF.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amiodarone
Description: Post operative AF after cardiac surgery. Amiodarone 150mg IV followed by 1 mg/min x 6 hours then 0.5 mg/min x 12 hours
Study: NCT05025527

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: biparametric MRI (bpMRI)
Description: Men go for the bpMRI for PCa (prostate cancer) screening, those who had a suspicious result will go for the next confirmation test
Study: NCT05414253

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Parallel Assignment
Description: Single-centre randomized, parallel design, clinical trial with a 2 week follow-up
Study: NCT05025527

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Prostate cancer antigen (PSA)
Description: Men go for the PSA test for PCa screening, those who had a suspicious result will go for the next confirmation test
Study: NCT01661647

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 3D knee kinematic assessment under local anesthesia
Description: 3D knee kinematic assessment under local anesthesia
Study: NCT05131971

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3888130B
Description: GSK3888130B will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3888130B
Description: GSK3888130B will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3888130B
Description: GSK3888130B will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3888130B
Description: GSK3888130B will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3888130B
Description: GSK3888130B will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3888130B
Description: GSK3888130B will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3888130B
Description: GSK3888130B will be administered.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered.
Study: NCT06243926

Intervention type: OTHER
Intervention: Sperm selection for ICSI
Description: Sperm selection for ICSI is a critical step to ensure the use of viable and healthy sperm for fertilization in vitro. The goal is to choose a sperm that has the best chance of resulting in a successful pregnancy.

Intervention type: OTHER
Intervention: Sperm selection for ICSI
Description: Sperm selection for ICSI is a critical step to ensure the use of viable and healthy sperm for fertilization in vitro. The goal is to choose a sperm that has the best chance of resulting in a successful pregnancy.
Study: NCT06500221

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: incentive spirometry
Description: The incentive spirometer is widely used in physical, speech, and respiratory therapy, as well as in preventing postoperative pulmonary infections and improving sputum clearance. Consequently, this study aims to further confirm the role and effectiveness of incentive spirometry in improving lung function, activity endurance, and long-term blood sugar and lipid indices in patients with Type 2 diabetes combined with sarcopenia.
Study: NCT06253429

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Thioctic Acid 333 MG Oral Capsule
Description: Antioxidant compound which serve as a cofactor for mitochondrial respiratory enzymes

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Captopril 25Mg Tab
Description: Oral angiotensin-converting enzyme inhibitors

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Captopril 25Mg Tab
Description: Oral angiotensin-converting enzyme inhibitors
Study: NCT04985656

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pevonedistat
Description: Pevonedistat IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Description: Decitabine tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cedazuridine
Description: Cedazuridine tablets
Study: NCT05450718

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: buprenorphine-naloxone
Description: Low-dose initiation of buprenorphine-naloxone protocol

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: buprenorphine-naloxone
Description: Standard clinical guidelines for a two-day buprenorphine-naloxone initiation
Study: NCT05333744

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: Prednisone po, 20mg per day for 2 weeks, if response (Plt 30-100×100\^g/L),gradually taper to the maintenance dose（5-10mg per day）until 6 weeks after delivery; if not response, gradually taper to withdrawal.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Prednisone po, 20mg per day for 2 weeks, if response (Plt 30-100×100\^g/L),gradually taper to the maintenance dose（5-10mg per day）until 6 weeks after delivery; if not response, gradually taper to withdrawal.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant Human TPO
Description: rhTPO im, 300U/kg per day for 2 weeks, if response (Plt 30-100×100\^g/L), taper to 300U/kg for twice per week until 6 weeks after delivery; if not response, drug withdrawal.
Study: NCT05666856

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Community Reinforcement And Family Training
Description: Community Reinforcement Approach and Family Training (CRAFT) is a scientifically based intervention designed to help concerned significant others (CSOs) to engage treatment-refusing substance abusers into treatment. This new intervention method was developed with the belief that the CSO can play a powerful role in helping to engage the substance user in treatment. It is often the substance user who reports that family pressure or influence is the reason sought treatment. CSOs benefit by becoming more independent and reducing their depression, anxiety and anger symptoms even if their loved one does not enter treatment.~CRAFT uses a positive approach versus confrontation, emphasizing learning new skills to cope with old problems. Some components include: how to stay safe, outlining the context in which substance abusing behavior occurs, teaching CSOs how to use positive reinforcers (rewards) and how to let the substance user suffer the natural consequences for their using behavior.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: We The Village Peer Community Forum
Description: An online peer support forum with other CSOs. Members of the forum post questions or comments to weekly peer-led discussions and receive responses and feedback from other CSO forum members. Members typically express concerns regarding their IP's wellbeing and ask other members to share any strategies they have employed when dealing with their IPs. Interactions typically, are based either in 12-Step strategies members have learned (usually through Al-Anon or Nar-Anon Family Groups or Family Training Workshops provided by treatment programs) or in CRAFT skills learned (usually from treatment programs or other We The Village members). A staff member from We The Village monitors forum interactions to ensure members are interacting respectfully.
Study: NCT05776602

Intervention type: DIAGNOSTIC_TEST
Intervention: Fast MRI (Neuromix)
Description: Diagnostic performance, correlation, agreement
Study: NCT05106790

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Educational support with peer counseling
Description: This group will receive peer counseling therapy sessions will be led by doctors who specialize in hypertension. Patients and their families will be the focus of the sessions. Face-to-face sessions will take roughly 25-30 minutes. Patients will receive spoken and written instructions based on their abilities during these sessions. The counseling sessions are geared toward overcoming both general and personal obstacles. The educational component will be delivered through smart booklets. Information on hypertension, blood pressure self-monitoring, and frequent systolic blood pressure (SBP) tests, as well as body weight and serum cholesterol values, are included in the instructional support. Food control, exercise therapy, and hypertension problems and their management will also be explored as non-pharmacological therapeutic approaches.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: mHealth intervention
Description: This group will receive mHealth intervention will include daily written and voice messages, and once weekly an educational-led video. This intervention module will be delivered through WhatsApp.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: mHealth intervention and Educational support with peer counseling
Description: This group will receive both Educational support (Smart booklets) with peer counseling sessions on a monthly basis and mHealth intervention will include daily written and voice reminders, and once weekly an educational led video.
Study: NCT04819620

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PN-232
Description: Active Drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PN-232
Description: Active Drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PN-232
Description: Active Drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching Placebo
Study: NCT04800666

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stellate Ganglion Block
Description: Patients underwent a stellate-ganglion block at the anterolateral aspect of the C6 vertebra. After local analgesia (lidocaine 2%), a 22-gauge Quincke needle was placed in the anterolateral aspect of the C6 vertebral body. When the needle contacted the bone, it was drawn back 1 mm. 5 mL of 0·5% ropivacaine was subsequently injected next to the stellate ganglion to produce a sympathetic block.The effect of the stellate-ganglion block on the sympathetic nervous system was confirmed by the presence of Horner's syndrome (ie, facial anhydrosis, enophthalmos, ptosis, swelling of the lower eyelid, miosis, and blood-shot conjunctiva), and an increase in the temperature of the right hand of at least 2°F from baseline.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Facial Nerve Block
Description: Operator touching the location of the mastoid, in the external auditory canal just below the front of the mastoid vertical needling.When touch the surface of the mastoid,adjust the needle across the front of the mastoid then slow needling about 1cm.The pin located below the stylomastoid foramen, and then injected drugs 5mL ( mecobalamin injection 1mg；lidocaine 60mg； dexamethasone 10mg )

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Facial Nerve Block
Description: Operator touching the location of the mastoid, in the external auditory canal just below the front of the mastoid vertical needling.When touch the surface of the mastoid,adjust the needle across the front of the mastoid then slow needling about 1cm.The pin located below the stylomastoid foramen, and then injected drugs 5mL ( mecobalamin injection 1mg；lidocaine 60mg； dexamethasone 10mg )

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Facial Nerve Block
Description: Operator touching the location of the mastoid, in the external auditory canal just below the front of the mastoid vertical needling.When touch the surface of the mastoid,adjust the needle across the front of the mastoid then slow needling about 1cm.The pin located below the stylomastoid foramen, and then injected drugs 5mL ( mecobalamin injection 1mg；lidocaine 60mg； dexamethasone 10mg )

Intervention type: DRUG
Group type: OTHER
Intervention: Mecobalamin Tablets
Description: oral Mecobalamin Tablets tid-8

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mecobalamin Tablets
Description: oral Mecobalamin Tablets tid-8

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mecobalamin Tablets
Description: oral Mecobalamin Tablets tid-8
Study: NCT04819620

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching Placebo
Study: NCT06006221

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Qi-gong relaxation exercise
Description: Qi-gong relaxation exercise is a mindfulness-based exercise and is a type of exercise that consists of breathing-compatible body movements and relaxation used to relax the body and mind, reduce stress, distract attention from negative thoughts, accelerate blood flow, and improve emotions.
Study: NCT04919551

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vicagrel
Description: Oral administration after fasting/high-fat meal/low-fat meal

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vicagrel
Description: Oral administration after fasting/high-fat meal/low-fat meal

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vicagrel
Description: Oral administration after fasting/high-fat meal/low-fat meal
Study: NCT04621786

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mecta Spectrum 5000Q paired with Soterix Medical 4X1 HD - ECT Multi-Channel Stimulation Interface
Description: The Mecta Spectrum 5000Q paired with Soterix Medical 4X1 HD-ECT Multi-Channel Stimulation Interface will reduce ECT current amplitude for amplitude-seizure titration.
Study: NCT05257161

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Emboshield NAV6™
Description: Embolic Protection System for Carotid Artery Revascularization ( distal - filter) + stent CGuardTM™

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mo.Ma™
Description: Embolic Protection System for Carotid Artery Revascularization ( proximal - occlusion) + stent CGuardTM™
Study: NCT05257980

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dietary supplement (ONS)
Description: At baseline, the investigating dietitian/nurse will record several measures, including clinical history and symptoms over the previous 24 hours. In addition, patients who are already receiving an ONS will continue their prescribed ONS for 1 day in which their gastrointestinal tolerance, ONS compliance and acceptability will be recorded. All patients will then receive standardised dietary advice in addition to one of the four trial ONS products daily for 28 days. The type of ONS will be agreed with the patient and the investigating dietitian/nurse, and the ONS prescription will be determined on an individual basis by the investigating dietitian/nurse responsible for the patient's nutritional management (1-3 ONS per day; aligned with guidelines set out within the Malnutrition Pathway). The type of ONS prescribed will be the same throughout the 28 days and will be taken orally.
Study: NCT05597891

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hēlo PE Thombectomy System
Description: Treatment with the Hēlo PE Thombectomy System for thromboembolectomy
Study: NCT05472220

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alpelisib
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alpelisib
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV during imaging

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV during imaging

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyperpolarized Carbon-13 (13C) Pyruvate
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyperpolarized Carbon-13 (13C) Pyruvate
Description: Given IV

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous Glucose Monitor (CGM)
Description: Self-applied devices that sit partially beneath the skin

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous Glucose Monitor (CGM)
Description: Self-applied devices that sit partially beneath the skin
Study: NCT04493034

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Art Therapy
Description: The art therapist will assist each participant in producing a bound collection of participant art works/writings for personal, group and/or caregiver inspiration, at the participant's request. For in-person sessions, a variety of studio-based art and writing materials will be available for participant selection and creation. Each session will be directed in the following manner:~* New therapeutic prompt or bridge from prior session~* Creative expression, opportunity for reflection, verbal sharing / processing, and a session summary~* Discussion of action plan for the next consecutive, at-home session (weekly assignment).~Possible wellness themes for each session (in-person or at-home) may include: mental health, physical health, emotional health, spiritual health, relational health (family and social), or occupational health/financial health.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Music Therapy
Description: Participants have the opportunity to engage in: learning an instrument, active music-making, receptive music-listening, singing, improvisation, song-writing, education on music technology, or music discussion. During in-person musical sessions the six psychosocial goals promoted by the music therapist include: 1) self-care/self-love, 2) support systems, 3) practicing positivity 4) gratitude 5) mindfulness/living in the moment, and 6) goal-setting.~For at-home assignments, participants will be asked to pick a song of the week that coincides with the theme/goal discussed in previous session(s). They will be asked to write a journal entry about the topic discussed. Journal entries can be freely written or a prompt/question can be provided. If participants do not have access to search for songs or listen to music as at home, they may select a piece from the session and be given lyrics and/or a recording on an .mp3 player returned at conclusion of study.
Study: NCT05131971

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered.
Study: NCT06457438

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Elecsys Anti-HEV IgG, IgM
Description: Diagnostic test used to determine antibodies in blood and serum.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Elecsys Anti-HEV IgG, IgM
Description: Diagnostic test used to determine antibodies in blood and serum.
Study: NCT06320067

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Ablative Body Radiotherapy (SABR)
Description: SABR is a way of giving focused high-dose radiotherapy. SABR given with a dose fractionation schedule of 30Gy in 3-5 fractions over 1-2 weeks to up to 5 metastatic lesions in the bone and/or non-regional (extra-pelvic) lymph nodes.